Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CG001419 in advanced solid tumors with NTRK alterations
CTR20222742Phase 2Active
- Sponsor
- Cullgen Inc.
- Start
- Jul 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of CG001419 in Nonhematologic neoplasms (6 arms), sponsored by Cullgen Inc. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose and 2 more. Started Jul 2023; status: active.
02
Drugs
CG001419
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222742.